TCT-644 Comparison of the new balloon-expandable SAPIEN 3 versus the SAPIEN XT. 30-day clinical outcome and echocardiographic data after transfemoral aortic valve implantation  by Fateh-Moghadam, Suzanne et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B263newer ESV-3 valve in patients (pts) undergoing TAVR on dual anti-
platelet therapy (DAPT).
METHODS All Pts were loaded with 600 mg Clp and 500 mg ASA the
day before TAVI. Platelet aggregation (Agg) were evaluated in all pts
by the Multiplate system (Dynabyte, Munich, Germany) before (T0),
directly after intervention (T1) and on T2 (day1), on T3 (day2), and on
T4 (day3). PA was simultaneously assessed at the above time points by
measuring CD62 P expression by ﬂow cytometry.60 pts (age 82.50.8
years, 21 (35 % male) with severe aortic stenosis and high surgical risk
(log Euroscore 17.21.2 %) underwent successfully TAVI with the ESV-
XT and 114 pts (age 81.50.6 years years, log Euroscore 21.4 þ1.4 %, 43
(37.7% male) underwent TAVI with the ESV-3.
RESULTS Adenosindiphosphat (ADP)- , arachidonic acid (ASPI) – and
collagen (coll) induced platelet Agg was inhibited to the same extent
in both valve types directly after TAVI under dual antiplatelet therapy
[ESV-XT (T1) versus ESV-3 3 (T1) : AggADP, (AUC): 16 (11-24) versus 19
(13-30); p¼0.514; AggASPI (AUC): 13(5-19) versus 12 (6-17);
p¼0.436.Agg coll (AUC): 13(5-19) versus 12 (6-17); p¼0.436]. There was
no signiﬁcant difference in platelet drop between both valve types
between day 0 and day3. [ESV-XT (T0T3) versus ESV-3 (T0T3): 55.2 
4.2 versus 63.5 8.1; p¼0.364. ] However there was an enhanced
expression of CD62P directly after implantation in pts with ESV-XT
compared to pts with the ESV-3. [ESV-XT versus ESV-3 :median
(25th;75th percentile) mean immunoﬂuorescence : CD62P : 7.4 (6.8-
8.6) versus 6.6 (6-7.9), p¼0.014; ] CD 62 P expression was associated to
the grade of paravalvular aortic regurgitation (AR) after valve im-
plantation. TAVI patients with AR grade 1 exhibited a signiﬁcantly
higher CD62P expression than patients with AR grade 0 or Trace post
implantation [ CD62P expression in AR grade 1 versus CD62P expres-
sion in AR (grade 0 or Trace) : median (25th;75th percentile) mean
immunoﬂuorescence :7.9 (7.3-9.1) versus 7.1 (6.4 -8.0); p < 0.001) ]
CONCLUSIONS Although platelet inhibition was similar in both valve
types, platelet activation was signiﬁcantly enhanced in pts with the
ESV-XT compared to the ESV-3 valve and was associated to the
amount of residual AR which was signiﬁcantly reduced by ESV-3,
which may have implications for thromboischemic events following
TAVR procedure.
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BACKGROUND Post-TAVI paravalvular aortic regurgitation (PVL) is
still one of the most important limitation of ﬁrst generation trans-
catheter aortic valve prosthesis. The Edwards SAPIEN 3 (ESV-3)
transcatheter heart valve incorporates a paravalvular sealing system
with an active 3 dimensional coaxial positioning and should herewith
address the problem of PVL. The aim of this study was to compare 30-
day clinical outcome and especially the incidence and magnitude of
post-TAVI paravalvular aortic regurgitation (PVL) after CT-guided
implantation of the newer generation transfemoral 14/16F-ESV-3 to its
precursor model 16/20F-ESV-XT using the Heart Navigator algoritm
for all pts.
METHODS Between August 2012 and October 2014, 209 consecutive
with high surgical risk underwent successfully transfemoral TAVI in
local anesthesia using either the ESV-XT (23,26,29 mm) or the ESV-3
(23, 26,29mm). CT-imaging including the Heart Navigator algorithm
was used for prosthesis size selection and valve implantation plane
selection. Clinical events and post-TAVI PVL was evaluated after 30
days according to the VARC-II criteria.
RESULTS Patients: 102 pts (mean age 81.97  0.5 years) with severe
aortic stenosis (pmean 47.6 1.52mmHg, mean AVA 0.76  0.11 cm2)
and high surgical risk (mean log Euroscore-I 16.9  0.86%) underwent
successfully TAVI with the ESV-XT and 107 pts (mean age 81.4  0.
6years, mean log Euroscore-I 20.2  1.39 with the ESV-3 in local
anesthesia. Procedural outcome: Device success was 101/102 (99.2%)
in ESV-XT and 100% in ESV-3, respectively. Compared to TAVI withthe ESV-XT, the ESV-3 procedures had shorter mean ﬂuoroscopy time
(10.0  0.5 min in vs 11.8  0.5 min, p¼ 0003, and less contrast media
was needed (188.9  5.6 ml versus 170.4  4.7 ml, p¼0.04. The pro-
cedure time (skin-to-skin) was not signiﬁcantly different (108.3  4.6
min vs 101.3  3.6 min, p¼0.496). In-Lab strokes and death did not
occur in both groups. 30-day clinical outcome: 30 day all-cause mor-
tality was similar among both valves implanted. (ESV-XT vs ESV-3:
2.9% vs 1.9%; p¼0.494) as was major/minor stroke rate (ESV-XT vs
ESV-3: 3.9% vs 1.9%; p¼0.333) . There was no signiﬁcant difference
between the two valve types concerning major vascular complication.
(ESV-XT vs ESV-3: 6.9% vs 9.3%; p¼0.322) and in the rate of new
pacemaker implantation (ESV-XT vs ESV-3: 16.7% vs 12.1%,n.s. ). 30-
day echocardiographic data: The rate of No/Trace AR was signiﬁcantly
higher in the ESV-3 compared to the ESV-XT (ESV-3 vs ESV-XT: 89.7%
vs 37.3%; p< 0.001). Mild AR ist found in in 62.7% after ESV-XT and in
only 10.3% after ESV-3-implantation (p<0.001). There was no severe
AR in both groups, in the ESV-XT there were 2.9 % of patients with
moderate AR compared to 0 in ESV3.
CONCLUSIONS Clinical outcome for both valves is excellent. Mild AR
is signiﬁcantly more frequent after ESV-XT-implantation. The
persistence of the result over time needs to be determined in further
studies.
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BACKGROUND With the advent of transcatheter aortic valve
replacement (TAVR), surgically high-risk or inoperable patients can
now undergo invasive aortic valve treatment. However, predicting the
left ventricular (LV) functional recovery after TAVR is still
challenging.
METHODS We prospectively enrolled patients undergoing TAVR at
the Stanford Transcatheter Heart Valve Program who provided con-
sent for the study. We measured conventional echocardiographic
parameters and novel metrics of ventricular strain (LV global longi-
tudinal strain, LV-GLS), in which a more negative value represents
better LV function. Patients were divided into improvement and
deterioration groups according to change in LV ejection fraction (EF)
before and 1 month after TAVR.
RESULTS A total of 87 patients were included in this study. Overall,
mean age and mean STS-predicted 30 day mortality were 83.58.9
years and 8.374.4 %, respectively. Mean LVEF and AV gradient were
56.614.7 % and 51.415.1 mmHg, respectively. We identiﬁed 53 pa-
tients who showed improvement in LVEF (delta LVEF¼4.04.3 %)
and 34 patients who showed deterioration in LVEF (delta LVEF¼
-5.66.3 %). The two groups had no signiﬁcant difference in baseline
clinical characteristics, including LVEF (p¼0.43, Figure A) and mean
AV gradient (p¼0.54). However, the improvement group had lower
baseline LV-GLS (p¼0.02, Figure B) and less tricuspid regurgitation at
baseline (1.10.5 vs. 1.50.8 , p¼0.04).
